ask our doctors

Hepatitis C

Get the facts on Hepatitis C treatment, diagnosis, staging, causes, types, symptoms. Information and current news about clinical trials and trial-related data, Hepatitis C prevention, screening, research, statistics and other Hepatitis C related topics. We answer all your qestions about Hepatitis C.

Question: At what temperature will the Hepatitis C virus be inactivated? I would like to disinfect utensils and dishes that are used by persons who have hepatitis C, perhaps using a dishwasher. Bleach has been said to be an effective way of killing the virus, but this is impractical for dishes and eating utensils. Is it possible at temperatures reachable by a dishwasher to inactivate the hepatitis C virus? But if a person were to bleed just a bit onto utensils or dishes, that would be a big risk. Hence, back to my original question.

Answer: Relax. The first answer was correct. You can not get hepatitis C that way. It is not transmitted by saliva or by casual contact. You can not get hepatitis C by sharing eating utensils, dishes, or drinking glasses, and you can not get it from any other casual contact. Hepatitis C is transmitted by infected blood. You would need to get infected blood INTO your bloodstream through a bleeding wound or a needle stick. (It is most commonly transmitted by sharing needles for drug use.) The only precautions you need to take when living with someone who has hepatitis C are: Do not share razors or toothbrushes with people who have Hep C, as these items could have blood on them, and the virus could stay alive on them for up to 4 days. Also, when helping someone who has hepatitis C deal with a bleeding injury, always wear gloves. As I said above, you can not get hepatitis C from sharing eating utensils, dishes, or drinking glasses, or by kissing, or by casual contact. It is not transmitted by saliva. It is only transmitted by blood.


Hepatitis C News

Aethlon Medical to Present Hepatitis C (HCV) Treatment Technology at the 32nd ...

MarketWatch (press release)
The clearance of circulating hepatitis C virions, including mutant strains, would inhibit the continued replication of drug-resistant viruses and decrease the likelihood of early onset resistance to emerging all-antiviral strategies.
 

BioLineRx Licenses Another Hepatitis C Drug From Genoscience

Wall Street Journal
BioLineRx Ltd. (BLRX) licensed another Hepatitis C treatment from French biotechnology company Genoscience, as the Israeli-based biopharmaceutical company expands into the field of Hepatitis C therapeutics. Hepatitis C is a blood-borne infection of the ...
 

As death nears, hepatitis C victim to give videotaped deposition in Desai case

Las Vegas Review-Journal
Rodolfo Meana, pictured here in 2008, is one of seven patients diagnosed with hepatitis C that has been genetically linked to the Endoscopy Center of Southern Nevada. Meana's doctors have told him he is terminally ill. » Buy this photo Dr. Dipak Desai ...
 

BioLineRx shares soar (again) on hep C pact; Anacor shares slide after GSK ...

FierceBiotech
Article | Follow @FierceBiotech @JohnCFierce: So does BioLineRx see itself as a hep C co. now that it has in-licensed a 2nd program, or is this about share price? Release | Follow @JohnCFierce @FierceMedDev: DNA-sequencing penetrates Norway's ...
 

Gilead Sciences Jumps on Hepatitis C Data

Pharmaceutical Processing
NEW YORK (AP) ? Shares of Gilead Sciences Inc. jumped Friday after the company reported further progress of GS-7977, a newly-acquired hepatitis C treatment still in clinical testing. THE SPARK: Gilead said Thursday that in a clinical trial, ...
 

RTT News

Gilead Rises on Hepatitis C Trial Results: San Francisco Mover
BusinessWeek
 

Is acupuncture a risk factor for hepatitis C in Asian patients?

Pulse (blog)
A Californian team investigated 494 patients with hepatitis C in order to determine the risk factors for this infection. 1 Specifically they wanted to find out whether the risk factors differ between various ethnic groups.
 

BioLineRX soars on second hepatitis C deal

MarketWatch
By Val Brickates Kennedy BOSTON (MarketWatch) -- Shares of BioLineRx soared 33% to $5.49 on Monday on news that the Israeli drug developer has licensed an experimental treatment for hepatitis C, dubbed BL-8030, from Genoscience and RFS Pharma.
 

Vertex Hep C Sales Growth Nears End

TheStreet.com
(TheStreet) -- Vertex Pharmaceuticals'(VRTX) fourth-quarter earnings report Thursday may represent the high-water sales mark for the hepatitis C drug Incivek -- with prescriptions already declining just seven months after launch.
 

Citybizlist

Idenix gets good news on hep C trial, but can't compete with Gilead
FierceBiotech